The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Human epidermal growth factor receptor 2 (HER2) overexpression occurs in 20-30% of breast cancers, correlating with aggressive disease and poorer outcomes.
• Trastuzumab, a HER2 receptor blocker, is a standard treatment for HER2-positive breast cancer, improving outcomes in early and metastatic stages.
• Key challenges include Trastuzumab's cardiac toxicity and the development of treatment resistance, driving research into novel therapeutic strategies.

Purpose of the Study:

• To review the role of Trastuzumab in HER2-positive breast cancer.
• To discuss the clinical efficacy and significant side effects of Trastuzumab.
• To highlight the ongoing development of targeted agents to overcome Trastuzumab resistance.

Main Methods:

• Review of clinical trial data and research findings on Trastuzumab efficacy and safety.
• Analysis of mechanisms underlying Trastuzumab resistance in HER2-positive breast cancer.
• Exploration of emerging targeted therapies and monoclonal antibodies.

Main Results:

• Trastuzumab significantly improves outcomes when added to standard chemotherapy for HER2-positive breast cancer.
• Cardiac myocyte injury, leading to congestive heart failure, is a major clinical side effect of Trastuzumab therapy.
• Emerging resistance patterns underscore the need for alternative and combination therapies.

Conclusions:

• Trastuzumab remains a cornerstone in HER2-positive breast cancer treatment, but its limitations require continuous therapeutic innovation.
• Further research is crucial for developing strategies to mitigate cardiac toxicity and overcome resistance, ultimately improving patient survival.
• The development of new targeted agents holds promise for enhancing treatment efficacy and managing resistance in HER2-positive breast cancer.